Asia Pacific Oncology Market Report

Asia Pacific Oncology Market Size

The size of the Asia Pacific oncology market was worth USD 57.03 billion in 2025. The regional market is anticipated to grow at a CAGR of 13.52% from 2026 to 2034 and be worth USD 178.55 billion by 2034 from USD 64.74 billion in 2026.

Oncology refers to the diagnostics, therapeutics, and supportive care services dedicated to the detection, treatment, and management of malignant diseases across the region. It includes modalities such as chemotherapy, targeted therapy, immunotherapy, radiation oncology, and surgical interventions, increasingly integrated with precision medicine approaches. The urgency of this sector is underscored by the region bearing the highest cancer burden globally, both in incidence and mortality.

As per the International Agency for Research on Cancer (IARC), in 2023, Asia accounted for nearly 50% of all new cancer cases worldwide, with over 10 million diagnoses, and more than 60% of cancer-related deaths. This disproportionate impact is driven by aging populations, lifestyle shifts, environmental exposures, and delayed diagnosis. In China alone, the National Cancer Center reported over 4.8 million new cancer cases annually, with lung, stomach, and liver cancers predominating due to high smoking rates, dietary factors, and hepatitis B prevalence. Similarly, in India, the Indian Council of Medical Research projects a 50% increase in cancer burden by 2035, with breast and cervical cancers rising rapidly among women. The region’s healthcare systems are further strained by uneven access to oncology infrastructure, with rural areas often lacking radiotherapy units or molecular diagnostic capabilities. These epidemiological and systemic realities position oncology as a critical public health priority, necessitating scalable, equitable, and technologically advanced care models.

MARKET DRIVERS

Rising Cancer Incidence Due to Demographic and Lifestyle Transitions

The escalating cancer burden in the Asia Pacific region is a primary catalyst for the expansion of oncology services and therapeutics, driven by demographic aging and rapid urbanization. As per the United Nations Department of Economic and Social Affairs, the number of individuals aged 60 and above in Asia Pacific is projected to reach 1.3 billion by 2050, nearly doubling from 2020 levels. This aging cohort is inherently more susceptible to oncogenic mutations, with cancer incidence increasing exponentially after age 50. In Japan, where a share of the population is already over 65, cancer affects one in two men and one in three women during their lifetime. Concurrently, lifestyle changes, such as increased tobacco use, sedentary behavior, processed food consumption, and alcohol intake, are fueling the rise of preventable cancers. Urban air pollution further exacerbates risk. These converging factors are creating an unprecedented demand for early screening, diagnostic imaging, and therapeutic interventions, particularly in middle-income nations where preventive infrastructure remains underdeveloped.

Increasing Adoption of Targeted Therapies and Immunotherapies

The integration of molecularly guided treatments into clinical practice is transforming oncology care across Asia Pacific, driving demand for advanced diagnostics and biologic therapies. Unlike conventional chemotherapy, targeted agents such as tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) offer improved efficacy and reduced toxicity by acting on specific genetic or immune pathways. Regulatory reforms are accelerating access. Additionally, local biotech firms in India and South Korea are developing biosimilars of trastuzumab and rituximab, improving affordability. These advancements are shifting treatment paradigms from generalized cytotoxic regimens to precision-driven strategies, expanding the therapeutic landscape and stimulating investment in companion diagnostics and next-generation sequencing platforms.

MARKET RESTRAINTS

Limited Access to Oncology Infrastructure in Rural and Underserved Areas

The severe disparity in oncology infrastructure between urban centers and rural communities is a critical barrier to effective cancer care in the Asia Pacific region. Diagnostic capabilities are equally constrained: in the Philippines, the Department of Health estimates that fewer than 20 hospitals offer next-generation sequencing for tumor profiling. This geographic inequity leads to delayed diagnosis and treatment initiation, contributing to poor survival outcomes. Moreover, the shortage of trained oncologists exacerbates the gap; in Vietnam, there is only one radiation oncologist per 2 million people, as reported by the Asian Clinical Oncology Society. Without strategic investment in decentralized care models and mobile diagnostic units, millions will remain excluded from life-saving interventions.

High Out-of-Pocket Expenditure and Inadequate Insurance Coverage

The financial burden of cancer treatment remains a prohibitive factor for a significant portion of the Asia Pacific population, primarily due to limited insurance coverage and high out-of-pocket costs. As per the Asia Pacific Observatory on Health Systems and Policies, in countries like India, Indonesia, and the Philippines, over 50% of total health spending is paid directly by patients, with cancer therapies among the most expensive. Even targeted therapies like trastuzumab, essential for HER2-positive breast cancer, are placing them beyond the reach of most patients. In Thailand, despite universal health coverage, the National Health Security Office excludes certain high-cost biologics, forcing patients to pay privately or forgo treatment. Similarly, in Malaysia, private insurers often impose caps on oncology drug reimbursement, limiting access to newer agents. The financial toxicity of cancer care leads to treatment abandonment. This economic barrier not only undermines clinical outcomes but also perpetuates health inequity, particularly among low-income and rural populations, constraining the scalability of advanced oncology interventions.

MARKET OPPORTUNITIES

Expansion of Precision Medicine and Genomic Testing Initiatives

The growing emphasis on precision oncology presents a transformative opportunity for healthcare systems and biotechnology firms across Asia Pacific. Governments and research institutions are launching large-scale genomic profiling programs to map regional cancer mutations and guide therapy selection. These initiatives are enabling the development of localized companion diagnostics and targeted therapies. Additionally, private-sector partnerships are accelerating access: Illumina and BGI Genomics have expanded sequencing facilities in Shanghai, Delhi, and Kuala Lumpur, reducing turnaround times to under few days. These advancements are laying the foundation for a new era of data-driven, personalized oncology care across the region.

Growth of Oncology-Focused Medical Tourism and Private Specialty Hospitals

The rise of high-quality, private oncology centers in countries like Thailand, India, and Singapore is creating a robust medical tourism ecosystem that attracts patients from across Asia and the Middle East. These centers combine advanced technology with concierge-style care, including visa assistance, accommodation, and multilingual support. Moreover, governments are actively supporting this sector. This convergence of affordability, quality, and accessibility is positioning the region as a global destination for cutting-edge cancer care, creating opportunities for device manufacturers, pharmaceutical companies, and service providers.

MARKET CHALLENGES

Fragmented Regulatory Pathways and Delays in Drug Approvals

The heterogeneity of regulatory frameworks across Asia Pacific countries creates significant delays in the approval and availability of novel oncology therapies, limiting patient access and discouraging innovation. Unlike the centralized European Medicines Agency or the U.S. FDA, each country maintains distinct requirements for clinical data, trial design, and post-marketing surveillance. In China, the National Medical Products Administration (NMPA) historically required local Phase III trials for foreign drugs, extending approval timelines to 4–5 years. Although reforms have reduced this to 18–24 months, discrepancies remain. India’s Central Drugs Standard Control Organization (CDSCO) faces backlog issues. In Indonesia and Vietnam, unclear classification of biosimilars and combination therapies leads to prolonged review cycles. This regulatory fragmentation forces multinational companies to prioritize markets with faster pathways, leaving patients in lower-income countries waiting years for life-saving treatments. Harmonization efforts remain limited, perpetuating inequities in access to innovation.

Shortage of Trained Oncology Professionals and Multidisciplinary Teams

The scarcity of specialized oncology personnel, including medical, radiation, and surgical oncologists, as well as oncology nurses and genetic counselors, poses a critical constraint on the delivery of comprehensive cancer care. Also, in Indonesia, the Indonesian Society of Clinical Oncology states that fewer than 400 certified medical oncologists serve a population of 270 million. This shortage is compounded by the lack of standardized training programs and interdisciplinary care models. In rural China, oncology services are often managed by general physicians without formal training, leading to suboptimal treatment planning. The absence of coordinated care teams undermines the effectiveness of precision medicine, which requires close collaboration between pathologists, radiologists, and molecular biologists. Without substantial investment in education, certification, and workforce retention, the region will struggle to deliver the complex, team-based care essential for modern oncology practice.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Cancer Diagnostics & Treatment Insights

The cancer treatment segment dominated the Asia Pacific oncology market by capturing an estimated 67.2% of total revenue in 2024. This dominance is primarily driven by the high cost and prolonged duration of therapeutic interventions, including chemotherapy, targeted therapy, immunotherapy, and radiation oncology. A key factor underpinning this segment’s leadership is the increasing adoption of high-cost biologic agents, particularly immune checkpoint inhibitors and tyrosine kinase inhibitors. Additionally, the expansion of proton therapy and robotic-assisted surgery in countries like China and India has further inflated treatment expenditures. Given that cancer therapy often spans months or years and involves multiple modalities, the cumulative financial outlay far exceeds that of diagnostics, reinforcing the treatment segment’s overwhelming share of the oncology budget.

The cancer diagnostics segment is the fastest-growing and is projected to expand at a CAGR of 14.3% from 2026 to 2034. This acceleration is fueled by the rising emphasis on early detection and molecular profiling to guide precision therapy. As per the World Health Organization, only 30% of cancers in low- and middle-income Asia Pacific countries are diagnosed at an early stage, prompting governments to invest in screening infrastructure. Liquid biopsy adoption is also surging. Next-generation sequencing (NGS) is becoming standard in urban centers. Additionally, AI-powered imaging analysis is improving radiological accuracy. These technological and policy-driven advancements are transforming diagnostics from a supportive function into a strategic pillar of oncology care, driving rapid market expansion.

By Indication Insights

The lung cancer segment was the largest indication in the Asia Pacific oncology market by accounting for 24.5% of total oncology spending in 2024. This dominance is rooted in its high incidence, aggressive progression, and growing reliance on expensive targeted and immune-based therapies. The high prevalence of smoking, particularly among men in countries like Indonesia and Vietnam, is a primary driver. Additionally, chronic exposure to indoor air pollution from cooking fuels and outdoor particulate matter (PM2.5) in cities like Delhi and Beijing significantly elevates risk. The shift toward precision medicine has further amplified market value. Given the combination of high patient volume, late-stage diagnosis, and premium-priced therapies, lung cancer remains the most economically significant oncology segment in the region.

The breast cancer segment is the fastest-growing indication and is projected to expand at a CAGR of 12.8%. This growth is driven by rising incidence, improved survival rates, and increased adoption of advanced therapies, particularly in younger and urban populations. Urbanization, delayed childbearing, and hormonal factors are contributing to this trend. The expansion of HER2-targeted therapies such as trastuzumab and biosimilars has significantly improved outcomes. Additionally, national screening programs are expanding. With increasing awareness, earlier diagnosis, and longer treatment durations due to improved survival, breast cancer is emerging as a high-growth, high-investment area in the regional oncology landscape.

By End-Use Insights

The hospitals segment represented the largest end-use in the Asia Pacific oncology market by commanding an estimated 63.7% of total revenue in 2024. This dominance is anchored in their role as primary hubs for integrated cancer care, combining diagnostics, surgery, chemotherapy, radiation therapy, and multidisciplinary tumor boards. In countries like China and India, tertiary care hospitals manage a significant share of advanced cancer cases, particularly those requiring radiotherapy or complex surgical interventions. Additionally, hospitals are the main recipients of government funding for cancer control programs. The concentration of advanced equipment, such as PET-CT scanners, linear accelerators, and robotic surgery systems, within hospital premises further consolidates their centrality. Moreover, hospitals serve as principal sites for clinical trials and drug adoption, enabling rapid integration of novel therapies. This comprehensive infrastructure, regulatory alignment, and clinical authority ensure hospitals remain the undisputed epicenter of oncology service delivery.

The diagnostic imaging centers segment is the fastest-growing end-use and is projected to expand at a CAGR of 13.9% from 2026 to 2034. This growth is driven by the rising demand for early and non-invasive cancer detection, particularly in urban and privately insured populations. In India, diagnostic chains like Metropolis and Dr. Lal PathLabs have integrated oncology imaging into preventive health packages, making screening more accessible. Artificial intelligence is enhancing diagnostic accuracy. Additionally, government initiatives are promoting early detection. The shift toward outpatient diagnostics, combined with technological innovation and preventive healthcare policies, is positioning imaging centers as critical gatekeepers in the cancer care continuum.

COUNTRY LEVEL ANALYSIS

China Oncology Market Insights

China held the largest share of the Asia Pacific oncology market at 35.1% of regional revenue in 2024. The country’s position is driven by its immense cancer burden, rapid healthcare modernization, and aggressive investment in precision oncology. With over 4.8 million new cancer cases annually, as reported by the National Cancer Center of China, lung, liver, and stomach cancers dominate due to high smoking rates, hepatitis B prevalence, and dietary factors. The government’s “Healthy China 2030” initiative has prioritized cancer control, leading to the establishment of several regional cancer centers and expanded access to immunotherapy and proton therapy. Local biotech firms like Innovent Biologics and BeiGene are developing PD-1 inhibitors and targeted agents, reducing reliance on imports. However, disparities persist between urban and rural areas, where diagnostic and treatment access remains limited.

India Oncology Market Insights

India secured a significant market share, which is fueled by rising incidence, private healthcare expansion, and growing biosimilar production, as noted by the Indian Brand Equity Foundation. The Indian Council of Medical Research projects an increase in cancer cases by 2035, with breast and cervical cancers rising rapidly. Private hospital chains like Apollo and Tata Memorial are integrating advanced diagnostics and immunotherapy into care pathways. India is also a global leader in biosimilar manufacturing, producing affordable versions of trastuzumab and rituximab. Government screening programs in urban centers are improving early detection, though rural access remains a challenge.

Japan Oncology Market Insights

Japan is distinguished by its advanced healthcare infrastructure and high adoption of innovative therapies, as per the Ministry of Health, Labour and Welfare. With one of the world’s oldest populations, cancer affects a large number annually. Japan leads in proton therapy and molecular diagnostics, with PMDA’s conditional approval pathway accelerating drug access.

Australia Oncology Market Insights

Australia is characterized by high clinical standards and strong research integration, as reported by the Australian Institute of Health and Welfare. With over 160,000 new cases annually, the country emphasizes early detection through national screening programs. Public and private hospitals adhere to evidence-based guidelines, and institutions like the Garvan Institute are pioneering genomic oncology. Medicare covers a wide range of therapies, though access to ultra-orphan drugs remains limited.

South Korea Oncology Market Insights

South Korea captures a notable share of the market, driven by technological sophistication and rapid regulatory adoption, as per the Korea Health Industry Development Institute. The country has one of the highest cancer incidence rates globally, but also among the highest survival rates due to early diagnosis and advanced care. Hospitals in Seoul and Busan are early adopters of AI-driven imaging and next-generation sequencing. The government fast-tracks approvals for breakthrough oncology drugs, and local firms are developing novel CAR-T therapies, positioning South Korea as a high-value innovation hub.

COMPETITIVE LANDSCAPE

The competitive landscape of the Asia Pacific oncology market is characterized by a dynamic interplay between global pharmaceutical leaders and emerging regional biotech firms vying for clinical influence and market access. Multinational corporations leverage their portfolios of targeted therapies and immunotherapies to maintain dominance in hospitals and specialty centers, particularly in high-income nations. At the same time, local manufacturers in India, China, and South Korea are gaining traction by producing biosimilars and cost-effective diagnostics, expanding reach into rural and underserved areas. Competition is intensifying around innovation speed, with companies racing to launch next-generation agents such as antibody-drug conjugates and CAR-T therapies. Regulatory divergence across countries necessitates tailored market entry strategies, favoring firms with agile compliance and local partnerships. The absence of universal reimbursement compels players to target private-pay segments, medical tourism, and government-funded pilot programs. Digital health integration, real-world evidence generation, and patient support initiatives are becoming differentiators. Success increasingly depends on holistic models that combine advanced therapeutics with diagnostics, education, and financial accessibility. The market rewards organizations that can deliver not only breakthrough treatments but also sustainable, equitable pathways to care across a fragmented and rapidly evolving healthcare environment.

KEY MARKET PLAYERS

Noteworthy Companies dominating the Asia Pacific oncology market are

• Aegerion Pharmaceuticals Inc.
• AbbVie Inc.
• Ability Pharma
• Acadia Pharmaceuticals Inc.
• Amgen Inc.
• Takeda Oncology
• Aslan Pharmaceuticals Ltd.
• Aspen Pharmacare Holdings Limited
• AstraZeneca
• Athenex, Inc.

TOP LEADING PLAYERS IN THE MARKET

• Roche has established a dominant presence in the Asia Pacific oncology market through its pioneering portfolio of targeted therapies and diagnostic solutions. The company’s monoclonal antibodies, trastuzumab for HER2-positive breast cancer and rituximab for lymphoma,s have become standard-of-care treatments across major healthcare systems in Japan, Australia, and South Korea. Roche has deepened its regional integration by collaborating with national cancer centers to implement companion diagnostics, ensuring biomarker testing precedes therapy initiation. It also partnered with Singapore’s Agency for Science, Technology and Research to develop localized genomic databases, supporting precision oncology adoption. By aligning pharmaceutical innovation with diagnostic infrastructure, Roche continues to shape treatment paradigms and reinforce clinical trust across diverse healthcare ecosystems in the region.
• Bristol Myers Squibb has significantly influenced oncology care in the Asia Pacific through its leadership in immunotherapy, particularly with the PD-1 inhibitor nivolumab. The drug is widely used in Japan, South Korea, and Australia for advanced melanoma, non-small cell lung cancer, and gastric cancers, where high PD-L1 expression rates enhance treatment efficacy. BMS has strengthened its regional footprint by engaging in early-access programs and outcome-based pricing models in countries like Thailand and Malaysia, improving affordability. It also funded real-world evidence studies at Seoul National University Hospital and the National Cancer Centre Singapore to validate long-term survival benefits. By combining clinical innovation with patient access programs and regional data generation, BMS has positioned itself as a key enabler of equitable immunotherapy adoption.
• AstraZeneca has emerged as a transformative force in the Asia Pacific oncology landscape through its focus on EGFR and ALK inhibitors for lung cancer, a leading cause of cancer mortality in the region. Drugs like osimertinib and brigatinib are now standard in first-line treatment for mutation-positive NSCLC patients across China, Japan, and India. AstraZeneca has expanded its impact by launching the “Lung Cancer Initiative Asia,” which supports early screening, molecular testing, and physician training in underserved areas. In 2023, the company introduced a digital pathology platform in collaboration with Tencent Health to improve EGFR testing accuracy in rural Chinese hospitals. It also accelerated drug availability through regulatory harmonization efforts with the ASEAN Joint Assessment Program. By integrating therapy development with diagnostic enablement and digital health, AstraZeneca is redefining lung cancer management and driving sustainable growth in high-burden markets.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the Asia Pacific oncology market are deploying multifaceted strategies to consolidate their presence and accelerate adoption. Strategic partnerships with national health authorities and cancer institutes are widely used to co-develop screening programs and treatment guidelines. Companies are investing in localized clinical trials and real-world evidence generation to support regulatory submissions and reimbursement dossiers. Expansion into biosimilars and affordable formulations is a growing focus, particularly in middle-income countries, to improve access. Digital integration through AI-powered diagnostics, tele-oncology platforms, and patient adherence apps is being leveraged to enhance care continuity. Additionally, firms are establishing patient support programs, including financial aid and molecular testing subsidies, to overcome economic barriers. These strategies collectively aim to bridge the gap between cutting-edge innovation and practical, scalable delivery in a region marked by diversity, inequity, and rising clinical demand.

RECENT MARKET DEVELOPMENTS

• In March 2023, Roche launched its Ventana PD-L1 (SP263) Assay in India and Indonesia, enabling hospitals to identify cancer patients eligible for immunotherapy, thereby strengthening its integration of diagnostics and therapeutics in high-growth markets.
• In August 2022, Bristol Myers Squibb initiated the Access to Oncology program in Vietnam and the Philippines, offering subsidized nivolumab treatment through hospital partnerships to improve affordability and expand patient access in underserved regions.
• In January 2024, AstraZeneca partnered with Tencent Health to deploy a digital pathology platform in rural China, enhancing EGFR testing accuracy and accelerating molecular diagnosis for lung cancer patients in remote areas.
• In November 2023, Roche expanded its collaboration with the National Cancer Centre Singapore to incorporate real-world data from Asian patient populations into global clinical development programs for upcoming oncology agents.
• In June 2023, AstraZeneca submitted osimertinib for inclusion in Thailand’s Universal Health Coverage list, aiming to secure public reimbursement and broaden access to first-line EGFR-targeted therapy for lung cancer patients.

MARKET SEGMENTATION

This Asia Pacific oncology market research report is segmented and sub-segmented into the following categories.

By Cancer Diagnostics & Treatment

• Cancer Diagnostics
  • Biopsy
  • Imaging
  • Immunohistochemistry
  • Tumor Biomarkers Test
  • In Situ Hybridization
  • Liquid Biopsy
• Cancer Treatment
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Others

By Indication

• Lungs Cancer
• Colorectal Cancer
• Breast Cancer
• Liver Cancer
• Bladder Cancer
• Head & Neck Cancer
• Prostate Cancer
• Others

By End-use

• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Academia
• Specialty clinics
• Others

By Country

• India
• China
• Japan
• South Korea
• Rest Of Asia Pacific